skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Melflufen - a peptidase-potentiated alkylating agent in clinical trials

Oncotarget, 2017-09, Vol.8 (39), p.66641-66655

Copyright: © 2017 Wickström et al. 2017 ;ISSN: 1949-2553 ;EISSN: 1949-2553 ;DOI: 10.18632/oncotarget.18420 ;PMID: 29029544

Full text available

Citations Cited by
  • Title:
    Melflufen - a peptidase-potentiated alkylating agent in clinical trials
  • Author: Wickström, Malin ; Nygren, Peter ; Larsson, Rolf ; Harmenberg, Johan ; Lindberg, Jakob ; Sjöberg, Per ; Jerling, Markus ; Lehmann, Fredrik ; Richardson, Paul ; Anderson, Kenneth ; Chauhan, Dharminder ; Gullbo, Joachim
  • Subjects: aminopeptidase ; cancer ; Medicin och hälsovetenskap ; melflufen ; Review ; targeted chemotherapy
  • Is Part Of: Oncotarget, 2017-09, Vol.8 (39), p.66641-66655
  • Description: Aminopeptidases like aminopeptidase N (APN, also known as CD13) play an important role not only in normal cellular functioning but also in the development of cancer, including processes like tumor cell invasion, differentiation, proliferation, apoptosis, motility, and angiogenesis. An increased expression of APN has been described in several types of human malignancies, especially those characterized by fast-growing and aggressive phenotypes, suggesting APN as a potential therapeutic target. Melphalan flufenamide ethyl ester (melflufen, previously denoted J1) is a peptidase-potentiated alkylating agent. Melflufen readily penetrates membranes and an equilibrium is rapidly achieved, followed by enzymatic cleavage in aminopeptidase positive cells, which results in trapping of less lipophilic metabolites. This targeting effect results in very high intracellular concentrations of its metabolite melphalan and subsequent apoptotic cell death. This results in a potency increase (melflufen melphalan) ranging from 10- to several 100-fold in different models. Melflufen triggers a rapid, robust, and an irreversible DNA damage which may account for its ability to overcome melphalan-resistance in multiple myeloma cells. Furthermore, anti-angiogenic properties of melflufen have been described. Consequently, it is hypothesized that melflufen could provide better efficacy but no more toxicity than what is achieved with melphalan, an assumption so far supported by experiences from hollow fiber and xenograft studies in rodents as well as by clinical data from patients with solid tumors and multiple myeloma. This review summarizes the current preclinical and clinical knowledge of melflufen.
  • Publisher: United States: Impact Journals LLC
  • Language: English
  • Identifier: ISSN: 1949-2553
    EISSN: 1949-2553
    DOI: 10.18632/oncotarget.18420
    PMID: 29029544
  • Source: GFMER Free Medical Journals
    PubMed Central
    Alma/SFX Local Collection
    SWEPUB Freely available online
Back to results list
Go to Previous pagePrevious Result  15 NextGo to Next page
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait